Torrent Pharmaceuticals has announced a significant milestone in its journey towards enhancing treatment options for gastroesophageal reflux disease (GERD) in India. On June 5, 2024, the company revealed that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialize Vonoprazan in India. This novel potassium-competitive acid blocker (P-CAB) will be marketed under Torrent’s own trademark.
Aman Mehta, Director of Torrent Pharma, expressed his optimism about the new venture, stating, “I am confident that the launch of Kabvie will aid in reducing the disease burden of GERD and further strengthen our gastrointestinal offerings, augmenting our position as a leading player within the Indian pharmaceutical market.”
GERD is a prevalent issue in India, with a 2019 study published in the Indian Journal of Gastroenterology noting that approximately 8.2% of the Indian population is affected, with urban areas showing a higher prevalence rate of 11.1%. The market for GERD treatments in India is substantial, valued at Rs 8,064 crore as of April 2024, according to AWACS MAT data, and has seen an 8% compound annual growth rate (CAGR) over the past four years.
Current treatments for GERD primarily involve Proton Pump Inhibitors (PPIs) such as Pantoprazole. However, Torrent Pharma's introduction of P-CABs like Kabvie is expected to provide patients with more effective and innovative treatment options, addressing a significant need in the Indian healthcare landscape.
